ODD - Oddity Tech Ltd. 0 WATCHERS

$LMMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc. EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer …

($LMMY) Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc. Some pretty big news. Their first PR after the acquisition and now active $LMMY ticker. Sub headline: "**EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION**" Some interesting bits below... ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become …

$LMMY Just got FDA Approval confirmed after hours friday (DD inside) I was watching some biotech stocks, and noticed a shell just got taken over and in the filings it says that Exousia Bio (and other Exousia subs) will be merged into $LMMY – This is pretty crazy considering LMMY …

Yes, there are plenty of quality growth stocks using the applications of Teck in other industries. Examples would be, ODD HOOD RKLB TOST.

Things to be thankful for: 1. Berkshire +7% since buying 2. Google +16% since buying (yeah I was late) 3. ODD +14% since buying

My current individual stock holdings are BRK.B, GOOG, and ODD Thots?

Seems like what is keeping ODD down are a bunch of analyst price target reductions. GS reasoning was due to “consumer weakness” - This hasnt been the case yet for ODD

Watching $ODD get trampled after that great earnings is nuts. Straight back to the downward trend.

Brutal, ODD gave back its ER gains

A few notes on ODD after coming down from an earnings high... We're probably going to see increasing cash burn with methodIQ launching. Fortunately the company has been hoarding cash, but the cash flow might look ugly for a few quarters. Ditto brand 4. Looks like a gap up to …

ODD raising 2025 guidance is baller. There are 6 weeks left in the year, and they're raising. Guiding $2.10/share on the low end. $12 cash per share, no debt. That was 11.9x EV/Earnings leading into this report. Growing 25% annually.

$ODD **Q3 net revenue $148M (+24% YoY)** and **nine-month net revenue $657M (+26% YoY)**. Q3 gross profit was $106M and gross margin improved to **71.6% (+170 bps)**. Q3 adjusted EBITDA was **$29M** and nine-month adjusted EBITDA was **$151M**. Q3 net income was **$18M** and adjusted net income was **$25M (+26% …

ODD lots with a great episode on the politics of AI, found [here](https://open.spotify.com/episode/7DifQVNr0WxbAVJF7fH4ua?si=8F_lhR_VSIy1aYGB1SdtHg). I've been watching this bubble and I'm fairly convinced this could be a big driver of future business. For example, there's going to be huge pressure on politicians to bring down electricity rates to pre AI levels. …

Oddity Tech (ODD) said Tuesday it launched Methodiq, a telehealth platform that provides tailored treatments through online diagnosis, removing the need for in-person doctor visits or pharmacy trips. The platform debuts with online treatments for acne, hyperpigmentation and eczema, with plans to expand into additional medical areas. Developed with board-certified …

ODD officially launching MethodIQ, previously referred to as brand 3. The goal is to launch personalized skin health products. Curious to see how this works out. I still think the market hasn't priced in any gain out of brand 3 and 4, much less the existing brands.

[https://investors.oddity.com/news-releases/news-release-details/oddity-launches-methodiq-telehealth-platform-reimagining-medical](https://investors.oddity.com/news-releases/news-release-details/oddity-launches-methodiq-telehealth-platform-reimagining-medical) >ODDITY Tech Ltd. (NASDAQ: ODD) today announced the launch of METHODIQ, a medical telehealth platform delivering customized, high-efficacy treatments powered by online diagnosis – without needing to go to a doctor’s office or get lost in a drug store.

Thank you Mr Market for letting me finish my ODD position